These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11010055)

  • 1. Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators.
    Monterroso VH; Rodriguez Chavez V; Carbajal ET; Vogel DR; Aroca Martinez GJ; Garcia LH; Cuevas JH; Lara Teran J; Hitzenberger G; Leao Neves P; Middlemost SJ; Dumortier T; Bunt AM; Smith RD
    Adv Ther; 2000; 17(2):117-31. PubMed ID: 11010055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
    Elliott WJ; Calhoun DA; DeLucca PT; Gazdick LP; Kerns DE; Zeldin RK
    Clin Ther; 2001 Aug; 23(8):1166-79. PubMed ID: 11558856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect on blood pressure control of switching from valsartan monotherapy to losartan/hydrochlorothiazide in Asian patients with hypertension: results of a multicentre open-label trial.
    Watanabe LA; Wei M; Sun N; Kim D; Chiang CE; Ke Y; Tseng CD; Coloma R; Vala M; Massaad R; Feig P; Guptha S
    Curr Med Res Opin; 2006 Oct; 22(10):1955-64. PubMed ID: 17022855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
    Manolis AJ; Grossman E; Jelakovic B; Jacovides A; Bernhardi DC; Cabrera WJ; Watanabe LA; Barragan J; Matadamas N; Mendiola A; Woo KS; Zhu JR; Mejia AD; Bunt T; Dumortier T; Smith RD
    Clin Ther; 2000 Oct; 22(10):1186-203. PubMed ID: 11110230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
    Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension.
    Roca-Cusachs A; Oigman W; Lepe L; Cifkova R; Karpov YA; Harron DW
    Acta Cardiol; 1997; 52(6):495-506. PubMed ID: 9542575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
    Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
    Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
    Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
    Oparil S; Williams D; Chrysant SG; Marbury TC; Neutel J
    J Clin Hypertens (Greenwich); 2001; 3(5):283-91, 318. PubMed ID: 11588406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
    Hermida RC; Ayala DE; Khder Y; Calvo C
    Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of valsartan and olmesartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring.
    Destro M; Scabrosetti R; Vanasia A; Mugellini A
    Adv Ther; 2005; 22(1):32-43. PubMed ID: 15943220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Stumpe KO
    Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine.
    Palatini P; Malacco E; Di SS; Carretta R; Dorigatti F; Bertocchi F; Mann J
    Eur J Clin Pharmacol; 2002 Jan; 57(11):765-70. PubMed ID: 11868797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension.
    Townsend R; Haggert B; Liss C; Edelman JM
    Clin Ther; 1995; 17(5):911-23. PubMed ID: 8595643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
    Palatini P; Dorigatti F; Mugellini A; Spagnuolo V; Varì N; Ferrara R; Bertocchi F
    Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
    Giles TD; Oparil S; Silfani TN; Wang A; Walker JF
    J Clin Hypertens (Greenwich); 2007 Mar; 9(3):187-95. PubMed ID: 17341994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.